A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2001
11/15/2001	WO2001085116A2 Synergistic antiplaque/antigingivitis oral composition
11/15/2001	WO2001085109A1 Novel quaternary compounds, compositions containing them, and uses thereof
11/15/2001	WO2001085106A2 Cosmetic agents containing 2-furanone derivatives
11/15/2001	WO2001085099A2 Polymeric delivery and release systems for oral care actives
11/15/2001	WO2001085093A2 Compounds and methods for modulating cerebral amyloid angiopathy
11/15/2001	WO2001076627A8 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
11/15/2001	WO2001047498A3 Hydrogel-driven layered drug dosage form comprising sertraline
11/15/2001	WO2001041733A3 Compressed tablet composition comprising a nsaid
11/15/2001	WO2001036656A3 A complex between hyaluronic acid and a biomolecule and its use
11/15/2001	WO2001036001A3 Interferon gamma conjugates
11/15/2001	WO2001019334A3 Pharmaceutical solutions of levosimendan
11/15/2001	WO2001017567A3 Improved container composition for diagnostic agents
11/15/2001	WO2001015737A3 Method for coupling molecules
11/15/2001	WO2001005434A3 Hyaluronic acid-protein conjugates
11/15/2001	WO2000064484A3 Conjugate having a cleavable linkage for use in a liposome
11/15/2001	US20010041786 Stabilized acylated insulin formulations
11/15/2001	US20010041738 Containing trace elements
11/15/2001	US20010041721 Beta blocker and a C3-C7 fatty acid or salt thereof; carteolol hydrochloride and sorbic acid for example; promotes penetration of beta-blocker into the eye
11/15/2001	US20010041697 Implanting in an animal an effective amount of melengestrol acetate and trenbolone acetate for increasing growth performance, suppressing estrus and preventing pregnancy in an animal prefererably heifer
11/15/2001	US20010041695 Orally administering to a post-menopausal woman a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine or salts
11/15/2001	US20010041693 Perfluoropolyether phosphate used as preservative in formulation for topical use, specifically cosmetic
11/15/2001	US20010041689 Bisphosphonate conjugates and methods of making and using the same
11/15/2001	US20010041685 Mucin synthesis inhibitors
11/15/2001	US20010041671 Ophthalmic formulations
11/15/2001	US20010041189 Dipeptide containing glutamic acid
11/15/2001	US20010041182 Stable activity antioxidant provitamin such as l-ascorbic acid-2-phosphate and alpha-tocopheryl phosphate
11/15/2001	US20010041172 Water-soluble polymer conjugates of artelinic acid
11/15/2001	US20010041166 The sheet pressure-sensitive adhesive layer containing a medicine; water insolubility; surface anesthesia, dentistry
11/15/2001	US20010041164 Pharmaceutical preparation for inhalation of an opioid
11/15/2001	DE10022247A1 Polyurethane used as rheology-modifier e.g. in cosmetics or pharmaceuticals, based on di-isocyanate, polyether-polyol and long-chain mono-alcohol, -thiol or -amine
11/15/2001	DE10022092A1 Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung The stabilized protein preparation and process for its preparation
11/15/2001	DE10019157A1 Verfahren zum Einbringen von Liganden in lebende Zellen A method for introducing ligands in living cells
11/15/2001	CA2691739A1 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo [b]thiophene and salts thereof
11/15/2001	CA2411244A1 Therapeutic pore-forming peptides
11/15/2001	CA2409679A1 Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy
11/15/2001	CA2408647A1 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
11/15/2001	CA2408594A1 Human monoclonal antibodies to dendritic cells
11/15/2001	CA2408571A1 Mammalian receptor proteins; related reagents and methods
11/15/2001	CA2408563A1 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
11/15/2001	CA2408464A1 Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
11/15/2001	CA2408352A1 Nontoxic vernix compositions and method of producing
11/15/2001	CA2408152A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
11/15/2001	CA2408112A1 Skin protectant spray compositions
11/15/2001	CA2408106A1 Opioid antagonist compositions and dosage forms
11/15/2001	CA2407962A1 Cosmetic agents containing 2-furanone derivatives
11/15/2001	CA2406686A1 Esterified polysaccharide products and .gamma.-lactone ring opened ketene dimer products containing the compositions, and process of making the same
11/15/2001	CA2395314A1 Compounds and methods for modulating cerebral amyloid angiopathy
11/14/2001	EP1153960A1 Process for producing a solid shaped form from low DE starch hydrolysates and/or coated with these starch hydrolysates
11/14/2001	EP1153615A1 Pharmaceutical formulation for intravenous or intramuscular octreotide administration
11/14/2001	EP1153613A1 Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism
11/14/2001	EP1153608A1 Stabilised protein preparation and process for the manufacture thereof
11/14/2001	EP1153601A1 Skin preparations for external use
11/14/2001	EP1152776A1 Biodegradable, injectable oligomer-polymer composition
11/14/2001	EP1152772A2 Liposome composition and method for administration of a radiosensitizer
11/14/2001	EP1152753A1 Combinations of formoterol and fluticasone propionate for asthma
11/14/2001	EP1152751A1 Desoxypeganine transdermal therapeutic system
11/14/2001	EP1152750A1 Spontaneously dispersible n-benzoyl staurosporine compositions
11/14/2001	EP1152749A2 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
11/14/2001	EP1152743A1 Skin sanitizing compositions
11/14/2001	EP1152734A1 Modified calycins
11/14/2001	EP1152723A1 Enzymatic treatment and prevention of hypertrophic skin
11/14/2001	EP1117720A4 Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier
11/14/2001	EP1066380B1 Soluble t cell receptor
11/14/2001	EP1003537B1 Composition comprising propolis and at least an essential oil
11/14/2001	EP1003484B1 Improved multiparticulate tablet with quick disintegration
11/14/2001	EP0923942B1 5alpha-REDUCTASE INHIBITORY PREPARATION FOR ORAL ADMINISTRATION, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF
11/14/2001	EP0922071B1 Polycarboxylic based cross-linked copolymers
11/14/2001	EP0904081B1 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
11/14/2001	EP0812198B1 Stabilization of prostaglandin compositions
11/14/2001	EP0804170B1 Method for making freeze dried drug dosage forms
11/14/2001	EP0799052B1 New antithrombotic formulation, process for its manufacturing, and use thereof
11/14/2001	CN1322141A PEG-urate oxidase conjugates and use thereof
11/14/2001	CN1322140A Stabilized preparations of beta-lactam antibiotic
11/14/2001	CN1322138A Protease inhibitors for use in treatment of psoriasis
11/14/2001	CN1322131A Nimesulide containing topical pharmaceutical compositions
11/14/2001	CN1322129A Electrically controlled transport of charged penetrants across barriers
11/14/2001	CN1321444A Composition contg. anthocyanidin
11/14/2001	CN1074762C Process for preparing chromium L-threonate, its preparing process and application
11/14/2001	CN1074660C Use of bilayer forming emulsifiers in nutritional compositions comprising divalent metal salts
11/13/2001	US6316669 Ophthalmology
11/13/2001	US6316652 Drug mitochondrial targeting agents
11/13/2001	US6316598 Oxidizing insoluble keratin in soluble oxidizing agent, such that a portion of disulfide bonds of are oxidized to form sulfonic acid residues, to obtain an oxidized insoluble solid fraction; separating; forming salt suspension; removing
11/13/2001	US6316505 For side effect reduction, transport of the drug to solid tumors and a reverse multiple drug resistance
11/13/2001	US6316497 For suppressing cell proliferation and neovascularization
11/13/2001	US6316481 Pharmaceutical composition containing proton pump inhibitors
11/13/2001	US6316473 Good drug release and absorption
11/13/2001	US6316460 Containing a heptenoic acid derivative and a tribasic phosphate salt as a stabilizer; hmg-coa reductase inhibitor
11/13/2001	US6316453 Aqueous pharmaceutical composition
11/13/2001	US6316424 Sulfated phosphatidylinositols, their preparation and use of the same
11/13/2001	US6316421 Pentaerythritol lipid derivatives and nuleic-acid complexes
11/13/2001	US6316418 Regulated apoptosis
11/13/2001	US6316417 Parenteral formulations comprising carbamazepine or its derivatives
11/13/2001	US6316190 Oligonucleotides which specifically bind retroviral nucleocapsid proteins
11/13/2001	US6316029 Rapidly disintegrating solid oral dosage form
11/13/2001	US6316025 Absorption upon digestion
11/13/2001	US6316022 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
11/13/2001	US6316021 Extensible mask including an adhesive matrix that can be stretched at least in the wet state
11/13/2001	US6316020 For therapy of gastric acid related diseases in mammals
11/13/2001	US6316019 For topical drug delivery
11/13/2001	US6316011 End modified thermal responsive hydrogels

1 ... 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 ... 1712